[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-adherence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-adherence":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,49,83,114,144,180,201,228,259,287,318,344,377,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635725","development-of-a-mobile-application-called-tansiyoritim-for-hypertension-patients-100635725",false,"NCT07556419","Development of a Mobile Application Called TansiyoRitim for Hypertension Patients","The Effect of a Mobile Application Developed for Hypertension Patients on Blood Pressure Control, Treatment Adherence, and Self-Efficacy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with hypertension at least 1 year prior to enrollment\n* Currently using antihypertensive medication\n* Able to use a smartphone\n* Able to measure blood pressure at home\n* No severe visual or hearing impairment\n* Able to communicate in Turkish\n* Literate\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Age under 18 or over 85 years\n* Presence of severe comorbid chronic disease affecting participation\n* Severe physical or cognitive impairment preventing participation\n* Body mass index (BMI) ≥ 30 kg\u002Fm²","ALL","18 Years","85 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Based on King's Theory of Goal Success, this project is designed to develop a mobile application called TansiyoRitim for individuals over the age of 18 diagnosed with hypertension. The research consists of the following phases: creating educational content, designing the mobile application, and evaluating the application and its effectiveness. Within the scope of the research, participants' blood pressure control, self-efficacy levels, and treatment adherence behaviors will be assessed using valid and reliable measurement tools, and the goal is to support these behaviors through the developed mobile health application. Participants' clinical treatment processes, pharmacological treatment adjustments planned by the physician, and changes in medication dosages will be excluded from the scope of the project. No intervention will be made in the medical treatment currently being administered during the study; participants' routine clinical follow-up and treatment processes will continue within the framework of standard care. Only educational and mobile app-based supportive interventions will be implemented within the scope of the research.",[27,28,29,30,31],"Hypertension","Mobile Application","Blood Pressure Control","Treatment Adherence","Self-Efficacy",[27,33,34,30,31,35],"mobile application","blood pressure control","King's Goal Achievement Theory","NOT_YET_RECRUITING","2026-06-16",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-03-20",{"name":46,"class":47},"Kafkas University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100637664","dynamic-multilevel-processes-of-recovery-in-therapeutic-communities-in-mexico-dico-model-100637664","NCT07588516","Dynamic Multilevel Processes of Recovery in Therapeutic Communities in Mexico (DICO Model)","Comprehensive Behavioral Community Dynamics (DICO): A Prospective Longitudinal Study of Multilevel Community Processes in Therapeutic Communities for Substance Use Treatment in Mexico","DICO","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Currently enrolled in a residential therapeutic community for substance use treatment\n* Minimum stay of at least 7 days prior to baseline assessment\n* Ability to understand and provide informed consent\n* Expected availability for participation during the 8-12 week follow-up period\n\nExclusion Criteria:\n\n* Acute psychotic symptoms or severe psychiatric decompensation that interferes with participation\n* Severe cognitive impairment limiting comprehension of study procedures\n* Current medical instability requiring immediate external intervention\n* Refusal to participate in any component of the study","MALE",{"count":59,"type":21},60,"12 Weeks","OBSERVATIONAL","This study aims to develop and empirically evaluate the Dinámica Integral Conductual Comunitaria (DICO) model, a multilevel framework that conceptualizes recovery from substance use disorders as a dynamic process emerging from the interaction between individual behavioral variables, social contingencies, and community-level factors within therapeutic communities in Mexico.\n\nA prospective longitudinal design with intensive repeated measures will be implemented over 8 to 12 weeks. Data will be collected using ecological momentary assessment (EMA), psychometric instruments, behavioral records, and semi-structured interviews.\n\nThe study seeks to model recovery trajectories as nonlinear dynamic systems, identifying critical transitions, instability patterns, and contextual moderators associated with treatment adherence and relapse risk.",[64,30],"Substance Use Disorder (SUD)",[66,67,68,69,70,71,72,73],"Therapeutic Communities","Ecological Momentary Assessment (EMA)","Psychological Flexibility","Craving","Community Reinforcement","Acceptance and Commitment Therapy","Multilevel Modeling","Dynamic Systems","2026-05-08",{"date":76,"type":40},"2026-05-14",{"date":78,"type":21},"2026-05-15",{"date":80,"type":21},"2026-10-02",{"name":82,"class":47},"Under The Tree Therapeutic Community",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100580360","the-evira-study-additional-support-during-obesity-treatment-100580360","NCT06836284","The Evira Study: Additional Support During Obesity Treatment","Evaluation of a Digital Treatment Tool in Combination With Obesity Medications","Inclusion Criteria:\n\n* Patients offered liraglutide or semaglutide in accordance with the clinic's routines.\n* Aged 12-17 years at the time of inclusion.\n* The family agrees to participate in a clinical study.\n\nExclusion Criteria:\n\n* Endocrine disorders other than well-controlled hypothyroidism.\n* Severe neuropsychiatric disorders that may affect adherence to the study.\n* Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion.\n* Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment.\n* Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome.\n* Patients deemed unsuitable for participation by the responsible physician.","12 Years","17 Years",{"count":93,"type":21},40,[24],"The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is:\n\n\\- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone?\n\nThis is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.",[97,30],"Childhood Obesity",[99,100,101,102],"Mobile Health","Self-Monitoring","Digital Treatment","Anti-Obesity Medication","RECRUITING","2026-04-29",{"date":106,"type":40},"2026-05-05",{"date":108,"type":40},"2026-02-13",{"date":110,"type":21},"2027-05-01",{"name":112,"class":47},"Karolinska Institutet",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":130,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100514081","peer-recovery-to-improve-polysubstance-use-and-mobile-telemedicine-retention-100514081","NCT05973838","Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention","Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area","PRISM","Inclusion Criteria:\n\nPatient participants in the RCT must be 18 or older; receive OUD treatment as part of the telemedicine program; and exhibit polysubstance use within the past three-months (i.e., use of one or more non-prescribed substances (excluding opioids and\u002For tobacco) by urine toxicology or self-report.\n\nExclusion Criteria:\n\n* Demonstrating active, unstable or untreated psychiatric symptoms, including mania and\u002For psychosis that would interfere with study participation\n* Inability to understand the study and provide informed consent in English",{"count":20,"type":21},[24],"The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) and reduce polysubstance use among patients with OUD and polysubstance use in underserved areas. The intervention is based on behavioral activation (BA) and is specifically designed to be implemented by a trained peer recovery specialist. In this hybrid, Type-1 effectiveness-implementation randomized controlled trial (RCT), the investigators will evaluate the effectiveness and implementation of Peer Activate vs. treatment as usual (TAU) over twelve months.",[126,127,30,128,129],"Polysubstance Addiction","Opioid Medication Assisted Treatment","Retention in Care","Substance-Related Disorders",[129,131,132,133],"Opioid-Related Disorders","Polysubstance Use","Mental disorders","2026-04-21",{"date":136,"type":40},"2026-04-27",{"date":138,"type":40},"2023-06-15",{"date":140,"type":21},"2027-09-01",{"name":142,"class":47},"University of Maryland, College Park",4,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":161,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100633295","telenursing-for-the-early-detection-and-management-of-side-effects-associated-with-cyclin-dependent-kinase-inhibitors-in-breast-cancer-patients-100633295","NCT07524829","Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients","NURSING-Preeffect: Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients","Inclusion Criteria:\n\n* Female patients aged ≥18 years\n* Histologically confirmed breast cancer\n* Ongoing treatment with CDK 4\u002F6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib)\n* Ability to understand and provide informed consent\n* Access to a telephone or digital communication device for telenursing follow-up\n\nExclusion Criteria:\n\n* Inability to comply with the study procedures\n* Cognitive impairment or psychiatric conditions interfering with participation\n* Participation in another interventional clinical trial that may affect study outcomes\n* Severe comorbidities limiting life expectancy or follow-up","FEMALE",{"count":153,"type":21},124,[24],"This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.\n\nPatients undergoing treatment with CDK inhibitors frequently experience adverse effects that may negatively impact treatment adherence, quality of life, and clinical outcomes. Early detection and timely management of these side effects are essential to optimize therapy and reduce complications, including unplanned hospitalizations and treatment interruptions.\n\nIn this study, participants are randomly assigned to one of two groups: standard care or standard care plus a structured telenursing follow-up program. The intervention consists of scheduled remote contacts (telephone or video consultations) conducted by trained nursing staff at predefined time points during treatment. These contacts aim to monitor symptoms, provide education, reinforce adherence, and facilitate early identification and management of treatment-related toxicities.\n\nThe primary objective of the study is to assess whether the telenursing intervention reduces the incidence and severity of treatment-related adverse events compared to standard care alone. Secondary objectives include evaluating its impact on emergency department visits, hospitalizations, treatment adherence, dose intensity, and patient-reported outcomes.\n\nThe study is currently recruiting participants across multiple centers. Results from this trial may provide evidence to support the integration of structured telenursing programs into routine oncology care, with the potential to improve patient safety, treatment continuity, and overall clinical outcomes.",[157,158,159,30,160],"Breast Cancer","Drug-Related Side Effects and Adverse Reactions","Chemotherapy Toxicity","Treatment-Related Toxicity",[157,162,163,164,165,166,167,168,30,169],"Telenursing","Telemedicine","Cyclin-Dependent Kinase Inhibitors","CDK4\u002F6 Inhibitors","Treatment Toxicity","Adverse Events","Supportive Care","Oncology Nursing","2026-04-09",{"date":172,"type":40},"2026-04-13",{"date":174,"type":40},"2024-04-09",{"date":176,"type":21},"2028-09",{"name":178,"class":179},"Azienda Sanitaria Locale di Asti","OTHER_GOV",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":48},"100476832","motivational-interviewing-at-intake-vs-intake-as-usual-on-client-engagement-in-addiction-treatment-100476832","NCT05489068","Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment","Adapting Intake Procedures to Improve Treatment Delivery in Addiction Treatment","Inclusion Criteria (client participants):\n\n* English-speaking adults seeking treatment for alcohol or other drug use at one of two outpatient addiction treatment programs\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures\n* Physically withdrawn from alcohol or other drugs\n\nInclusion Criteria (personnel participants):\n\n* English-speaking adults currently employed at one of the two outpatient addiction treatment programs\n* Provision of electronic informed consent\n\nExclusion Criteria (client participants):\n\n* Experiencing severe withdrawal symptoms\n* Actively psychotic, manic, and\u002For suicidal\n\nExclusion Criteria (personnel participants):\n\n* current position: facility owner or clinical director",{"count":188,"type":21},150,[24],"This K23 study is an effectiveness-implementation hybrid type I design to determine the effectiveness of Motivational Interviewing at Intake (MII), relative to intake-as-usual on client engagement and mechanisms of engagement among adults seeking outpatient addiction treatment. We also will obtain personnel feedback on the feasibility of implementing MII into standard practice by having personnel from the addiction treatment study sites complete implementation climate measures before Motivational Interviewing (MI) training and post-clinical trial, as well as an individual interview on implementation feasibility post-trial.",[129,30],"2026-03-05",{"date":194,"type":40},"2026-03-09",{"date":196,"type":40},"2022-03-16",{"date":198,"type":21},"2026-12-01",{"name":200,"class":47},"University of New Mexico",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":113},"100563849","oursleepkit-to-support-cpap-adherence-100563849","NCT06621511","OurSleepKit To Support CPAP Adherence","OurSleepKit: A Couple-focused m-Health Intervention to Support Adherence to CPAP Treatment","Inclusion Criteria:\n\n* patients should be males or females (age≥18 years) with diagnosed OSA and candidates for CPAP therapy (with any type of pressure delivery mode), and are cohabiting with their partner for at least one year\n* The partners of eligible patients will be recruited if they are not diagnosed with OSA and not using CPAP\n* both partners should have their own mobile devices with access to the internet\n\nExclusion Criteria:\n\n* have a diagnosis of a sleep disorder other than OSA based on a polysomnogram (e.g., central sleep apnea, narcolepsy, or periodic limb movement disorder)\n* have planned bariatric surgery (as they typically quit CPAP after surgery)\n* have a partner using CPAP\n* are pregnant because the changes in respiration and sleep quality occurring with pregnancy may confound the results.\n* couples with one or both partners doing regular overnight shift work or those unable to speak or write in English will be excluded.",{"count":209,"type":21},360,[24],"The goal of this clinical trial is to learn if a couple-focused mobile health intervention will improve the use of continuous positive airway pressure (CPAP), the primary treatment option for obstructive sleep apnea (OSA). Participants include newly diagnosed patients with OSA who are candidates for CPAP treatment and their partners. The couples will received supportive information and resources on their mobile devices before CPAP begins and continuing for 6 months into CPAP treatment. Their interaction with the resources is self-paced and the time sent engaging with the information is up to them. Participants will be asked to answer questions independently at five points: before CPAP, and after using CPAP for 1-week, 1-month, 3-months and 6-months. Those questions are about their experience of using CPAP, how the partner is involved in CPAP treatment, and symptoms and quality of life. At the end of the study, some couples may be contacted for a virtual discussion about your experience regarding study participation which lasts approximately 1 hour.",[213,214,30],"Obstructive Sleep Apnea","CPAP Treatment",[213,214,99,30,216,217],"Dyadic Coping","Couple","2026-01-30",{"date":220,"type":40},"2026-02-03",{"date":222,"type":40},"2024-12-03",{"date":224,"type":21},"2028-07-31",{"name":226,"class":227},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":244,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":48},"100554029","alcohol-misuse-treatment-to-patients-newly-diagnosed-with-alcohol-related-liver-disease-a-randomized-controlled-trial-100554029","NCT06493773","Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial","Alcohol Misuse Treatment Delivered in the Hepatology Clinic to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial","Inclusion criteria\n\n* Age \\> 18 years\n* Newly diagnosed alcohol-related liver disease, defined as within six months from baseline visit.\n* A liver stiffness above 8.0 kPa with 10 successful measurements and an interquartile range of less than 30% as assessed with transient elastography.\n* Excessive alcohol consumption defined as \\>7 units\u002Fweek for women and \\>14 units\u002Fweek for men within the previous year.\n* The patient is able to understand the purpose of the study and give informed oral and written consent to participate.\n\nExclusion criteria\n\n* Not enough proficiency in Danish to participate in interviews and questionnaires.\n* Pregnancy\n* Ongoing specialized AUD treatment. Self-help groups and AUD counselling at general practitioners are not counting as specialized AUD treatment in this study.",{"count":236,"type":21},221,[24],"To evaluate the efficacy of systematically offering newly diagnosed ALD patients to AUD treatment, in the hepatology clinic, on alcohol abstinence after 6 months. The investigators will conduct a randomized controlled superiority trial with parallel group design, hypothesis blinding and blinded outcome assessment comparing A) a offer to specialized AUD treatment (intervention) and B) standard care (control). Existing observational cohort ALD members will contribute to the control group in addition to the randomized controls. The primary outcome is abstinence throughout the last 30 days assessed 6 months after randomization.",[240,241,30,242,243],"Liver Diseases, Alcoholic","Alcohol Use Disorder","Alcoholism","Liver Disease; Alcohol-Related",[245,246,247,248,249],"Alcoholic liver disease","Alcohol use disorder","Alcohol treatment","randomized clinical trial","hepatology clinic","2025-11-14",{"date":252,"type":40},"2025-11-18",{"date":254,"type":21},"2025-11-15",{"date":256,"type":21},"2029-04-01",{"name":258,"class":47},"Zealand University Hospital",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":265,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":48},"100604059","the-effects-of-a-solution-focused-approach-on-psychosocial-adjustment-and-treatment-compliance-in-individuals-diagnosed-with-schizophrenia-100604059","NCT07144592","The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia","Inclusion Criteria:\n\n* Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria,\n\nBeing between 18 and 65 years of age,\n\nBeing literate and verbally communicative,\n\nBeing clinically stable (not exhibiting symptoms of acute psychosis),\n\nBeing registered with a Community Mental Health Center (CMHC) and receiving regular services,\n\nBeing cognitively competent enough to participate in individual interviews during the research process,\n\nBeing an individual currently receiving psychiatric treatment and taking medication,\n\nAgreeing to participate voluntarily in the study and signing a written informed consent form.\n\nExclusion Criteria:\n\n* those who do not meet the inclusion criteria",true,"65 Years",{"count":59,"type":21},[24],"The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.\n\nThe study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).\n\nThe experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).",[271,272,30],"SCHIZOPHRENIA 1 (Disorder)","Psychosocial Adaptation",[274,275,276,277],"treatment adherence","Schizophrenia","solution-focused therapy,","psychiatric nursing","2025-08-20",{"date":280,"type":40},"2025-08-27",{"date":282,"type":40},"2025-01-01",{"date":284,"type":21},"2025-10-25",{"name":286,"class":47},"Muş Alparslan University",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":304,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100600579","interactive-vs-standard-video-education-for-improving-outcomes-in-hemodialysis-patients-100600579","NCT07099326","Interactive vs. Standard Video Education for Improving Outcomes in Hemodialysis Patients","Examining the Effects of Interactive Versus Conventional Video-Based Education on Activation, Treatment Adherence, and Weight Changes in Dialysis Patients: A Randomized Clinical Trial Protocol","Inclusion Criteria:\n\n1. Willingness to participate in the study;\n2. Literate (ability to read and write);\n3. Alertness and orientation to time, place, and person sufficient to respond to questions;\n4. No history of hearing or visual impairments;\n5. No cognitive disorders;\n6. Possession of a personal mobile phone or any other device capable of running interactive videos, and the ability to use it;\n7. No use of psychoactive medications;\n8. Confirmed diagnosis of chronic kidney disease by a nephrology specialist and having a medical record in the dialysis unit;\n9. Age between 18 and 65 years.\n\nExclusion Criteria:\n\n1. Withdrawal from the study at any stage;\n2. Failure to receive and watch the provided videos;\n3. Patient death;\n4. Transfer to a healthcare center outside the coverage of Shahid Beheshti University of Medical Sciences.",{"count":295,"type":21},165,[24],"The goal of this clinical trial is to find out if educational videos-especially interactive ones-can help people on dialysis better manage their treatment.\n\nResearchers want to answer the following main questions:\n\nCan interactive or conventional video-based education help patients better understand and follow their treatment plan? Does this type of education improve patients' ability to control their weight changes between dialysis sessions? Does this type of education improve patients' activation? Is interactive video education more effective than regular (non-interactive) video education?\n\nWhat Will Happen in the Study:\n\nAdults on hemodialysis will take part in the study.\n\nThey will be randomly assigned to one of three groups:\n\nGroup A: Will receive 10 interactive educational video sessions (30 minutes each).\n\nGroup B: Will receive the same videos but in a non-interactive format. Group C (Control Group): Will receive routine education normally given at the dialysis center.\n\nVideos will be watched on a web platform. Interactive videos include pop-up questions and scenario-based feedback.\n\nAll participants will be followed up immediately, 1 month, and 3 months after the program ends.\n\nWhat Participants Will Do:\n\nWatch educational videos over several days (totaling 5 hours).\n\nAnswer questions and engage in follow-up group discussions.\n\nComplete surveys about their knowledge, treatment adherence, and health behaviors.\n\nGet weighed before and after dialysis sessions to monitor fluid retention.\n\nThis study aims to improve how dialysis patients manage their condition and to help healthcare providers design better educational tools.",[299,300,301,302,303,30],"Hemodialysis","Nurse","Educational Videos","Patient Activation","Weight Change",[305,306,302,307,308,309],"Interactive Video-Based Education","Conventional Video-Based Education","Patient Treatment Adherence","Patients' Weight Changes","Dialysis","2025-07-31",{"date":312,"type":40},"2025-08-05",{"date":312,"type":21},{"date":315,"type":21},"2025-10-05",{"name":317,"class":47},"Shahid Beheshti University of Medical Sciences",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":265,"sex":151,"minAge":17,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":48},"100464323","1-versus-2-hours-post-meal-glucose-monitoring-in-gestational-diabetes-on-treatment-100464323","NCT05326204","1 Versus 2 Hours Post Meal Glucose Monitoring in Gestational Diabetes on Treatment","1 Versus 2 Hours Post Meal Self Monitoring Blood Glucose in Gestational Diabetes Mellitus on Treatment-A Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n* Gestational diabetes diagnosed based on National Institute for Health and Care Excellence guideline\n* requiring treatment either with metformin alone or combined with insulin\n\nExclusion Criteria:\n\n* type 1 and 2 diabetes\n* bad obstetrics history\n* underlying medical disorders such as Systemic Lupus Erythematosus\n* fetal anomaly\n* delivery elsewhere","45 Years",{"count":327,"type":21},2954,"A study to compare between 1 and 2 hours post meal blood glucose monitoring in patients with Gestational Diabetes Mellitus requiring treatment.",[330,30],"Gestational Diabetes",[332,333,334],"Gestational diabetes","treatment","glucose monitoring","2025-06-09",{"date":337,"type":40},"2025-06-12",{"date":339,"type":40},"2021-12-30",{"date":341,"type":21},"2025-12-29",{"name":343,"class":47},"National University of Malaysia",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":265,"sex":57,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":113},"100485538","improving-hiv-testing-linkage-and-retention-in-care-for-men-through-uu-messaging-100485538","NCT05602376","Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging","Inclusion Criteria:\n\nAIM 1:\n\n1. male\n2. aged ≥15 years\n3. present a study issued invitation card to site receptionist\n4. ability to provide informed consent.\n\nAIM 2:\n\n1. cis-gender men\n2. aged ≥15 years\n3. newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care\n4. live in Buffalo City or Cape Town Metro Health Districts\n5. provide written informed consent","15 Years",{"count":352,"type":21},3642,[24],"This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (\\\u003C200 copies\u002FmL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).",[356,357,30],"HIV Infections","Men",[359,360,357,361,362,363,364,365,366,367],"HIV","HIV testing","U=U","Viral suppression","Treatment as Prevention","Viral load","ART uptake","Undetectable","Untransmittable","2024-10-30",{"date":370,"type":40},"2024-11-01",{"date":372,"type":40},"2023-03-31",{"date":374,"type":21},"2027-05-31",{"name":376,"class":47},"Desmond Tutu HIV Foundation",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":48},"100552698","taiwan-interstitial-lung-disease-multi-center-investigation-and-registry-100552698","NCT06476470","Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","A Prospective Multi-center Registry for Fibrotic Lung Disease, Focusing on Clinical Phenotype, Physical Parameters, Image Analysis, and Precision Medicine in Taiwan","TAILI","Inclusion Criteria:\n\n1. Aged over 18 years old.\n2. Diagnosed as ILD by a pulmonologist, rheumatologist or radiologist\n3. Various casue of ILD, including Idiopathic pulmonary fibrosis (IPF), Connective tissue disease-associated interstitial lung disease (CTD-ILD), Unclassifed ILD, drug-induced ILD, lymphangioleiomyomatosis (LAM), and sarcoidosis-associated ILD.\n\nExclusion Criteria:\n\n1. Under 18 years of age.\n2. Failure to express informed consent in person.",{"count":386,"type":21},10000,"The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol.\n\nKey components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests.\n\nThe main questions the registry aims to answer are:\n\n1. Differences in all-cause mortality among ILD patients of different etiologies.\n2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies.\n3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies.\n4. Predictive ability of HRCT imaging features for mortality risk in ILD patients.\n5. Impact of comorbidities on the mortality risk of ILD patients.\n6. Predictive ability of biomarkers for disease progression and mortality.",[389,390,391,30,392],"Interstitial Lung Disease","Comorbidities and Coexisting Conditions","Pulmonary Arterial Hypertension","Function Impaired Respiratory","2024-06-24",{"date":395,"type":40},"2024-06-26",{"date":397,"type":40},"2024-03-10",{"date":399,"type":21},"2035-12-31",{"name":401,"class":47},"Taichung Veterans General Hospital",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":410,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":420,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":48},"100544790","improving-quality-of-life-in-older-patients-with-frailty-and-hematological-cancer-through-geriatric-assessment-100544790","NCT06373471","Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment","Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment and Treatment; A Randomized Controlled Trial. IMPROVE","IMPROVE","Inclusion Criteria:\n\n* Age ≥70 years\n* New diagnosis or progression\u002Frelapse of acute leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, chronic myelomonocytic leukemia or myelofibrosis\n* Scheduled systemic cancer treatment or initiated systemic cancer treatment within 6 weeks\n* Geriatric 8 frailty score of ≤14 at screening\n* Life expectancy \\> 6 months\n* Not hospitalized at the time of inclusion\n\nExclusion Criteria:\n\n* Current systemic treatment for other coexisting cancer. Patients receiving anti-hormone treatment for breast cancer or prostate cancer are not excluded, if no evidence of disease progression (radiological\u002Fbiochemical) in past 3 months or if treatment is adjuvant.\n* Having consulted a geriatric outpatient clinic past 6 months\n* Patients in need of specialized neuro-rehabilitation\n* Unable to understand Danish\n* Unable to give written informed consent","70 Years",{"count":412,"type":21},152,[24],"The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks.",[416,30,417,418,419],"Hematologic Malignancy","Treatment Complication","Frailty","Quality of Life",[421],"Comprehensive Geriatric Assessment","2024-04-17",{"date":424,"type":40},"2024-04-18",{"date":426,"type":40},"2024-04-02",{"date":428,"type":21},"2026-09-30",{"name":430,"class":47},"Odense University Hospital"]